XORTX Therapeutics (XRTX) Cash from Operations (2022)

XORTX Therapeutics (XRTX) posted Cash from Operations of 13838770.24 for Q4 2022, down 1554.36% on a QoQ basis from 951535.92 in Q3 2022.

XORTX Therapeutics (XRTX) Cash from Operations (2022) Analysis & Trends

XORTX Therapeutics' Cash from Operations history runs 1 years deep, the most recent figure standing at 13838770.24 for Q4 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Cash from Operations (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-19.59 Mn
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	201.34 Mn
4	NuCana	279.75 Bn	279.75 Bn	-	-1.53 Mn
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	1.43 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	1.08 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-354.17 Mn
10	XORTX Therapeutics	20.40 Mn	20.40 Mn	-	-

Download Data